BRIEF-Exicure, Inc. Announces Purchase Agreement With Gpcr Therapeutics Inc.

Reuters

23 Jan

BRIEF-<a href="https://laohu8.com/S/XCUR">Exicure, Inc.</a> Announces Purchase Agreement With Gpcr <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc.

Exicure Inc XCUR.O:

EXICURE, INC. ANNOUNCES PURCHASE AGREEMENT WITH GPCR THERAPEUTICS INC.
EXICURE INC: ACQUIRED FROM GPCR ALL OF ISSUED AND OUTSTANDING EQUITY SECURITIES OF GPCR THERAPEUTICS USA INC
EXICURE - CO, GPCR ENTER LICENSE AND COLLABORATION AGREEMENT TO FURTHER DEVELOP, COMMERCIALIZE GPCR’S TECHS RELATED TO CERTAIN IP, PATENTS

Source text: ID:nBw9fFpRGa

Further company coverage: XCUR.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2505701720"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505701720\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2505701720?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-23 05:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505701720","market":"us","top_or_hot":-1,"title":"BRIEF-Exicure, Inc. Announces Purchase Agreement With Gpcr Therapeutics Inc.","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/XCUR\">Exicure, Inc.</a> Announces Purchase Agreement With Gpcr <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc.</title></head><body><p>Exicure Inc <span>XCUR.O</span>:</p><ul><li><p>EXICURE, INC. ANNOUNCES PURCHASE AGREEMENT WITH GPCR THERAPEUTICS INC.</p></li><li><p>EXICURE INC: ACQUIRED FROM GPCR ALL OF ISSUED AND OUTSTANDING EQUITY SECURITIES OF GPCR THERAPEUTICS USA INC</p></li><li><p>EXICURE - CO, GPCR ENTER LICENSE AND COLLABORATION AGREEMENT TO FURTHER DEVELOP, COMMERCIALIZE GPCR’S TECHS RELATED TO CERTAIN IP, PATENTS</p></li></ul><p>Source text: <span>ID:nBw9fFpRGa</span></p><p>Further company coverage: <span>XCUR.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>BRIEF-Exicure, Inc. Announces Purchase Agreement With Gpcr Therapeutics Inc.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Exicure, Inc. Announces Purchase Agreement With Gpcr Therapeutics Inc.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-23 05:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<title>BRIEF-<a href=\"https://laohu8.com/S/XCUR\">Exicure, Inc.</a> Announces Purchase Agreement With Gpcr <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc.</title><p>Exicure Inc <span>XCUR.O</span>:</p><ul><li><p>EXICURE, INC. ANNOUNCES PURCHASE AGREEMENT WITH GPCR THERAPEUTICS INC.</p></li><li><p>EXICURE INC: ACQUIRED FROM GPCR ALL OF ISSUED AND OUTSTANDING EQUITY SECURITIES OF GPCR THERAPEUTICS USA INC</p></li><li><p>EXICURE - CO, GPCR ENTER LICENSE AND COLLABORATION AGREEMENT TO FURTHER DEVELOP, COMMERCIALIZE GPCR’S TECHS RELATED TO CERTAIN IP, PATENTS</p></li></ul><p>Source text: <span>ID:nBw9fFpRGa</span></p><p>Further company coverage: <span>XCUR.O</span></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUA5GH44K:1","article_id":"2505701720","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505701720","pubTimestamp":1737582837,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Exicure, Inc. Announces Purchase Agreement With Gpcr Therapeutics Inc.Exicure Inc XCUR.O:EXICURE, INC. ANNOUNCES PURCHASE AGREEMENT WITH GPCR THERAPEUTICS INC.EXICURE INC: ACQUIRED FROM GPCR ALL","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XCUR":"Exicure, Inc."},"translate_title":"简介-Exicure公司宣布与Gpcr治疗公司达成购买协议。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XCUR":0.9},"content_text":"BRIEF-Exicure, Inc. Announces Purchase Agreement With Gpcr Therapeutics Inc.Exicure Inc XCUR.O:EXICURE, INC. ANNOUNCES PURCHASE AGREEMENT WITH GPCR THERAPEUTICS INC.EXICURE INC: ACQUIRED FROM GPCR ALL OF ISSUED AND OUTSTANDING EQUITY SECURITIES OF GPCR THERAPEUTICS USA INCEXICURE - CO, GPCR ENTER LICENSE AND COLLABORATION AGREEMENT TO FURTHER DEVELOP, COMMERCIALIZE GPCR’S TECHS RELATED TO CERTAIN IP, PATENTSSource text: ID:nBw9fFpRGaFurther company coverage: XCUR.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1}}}